Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Variants

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44335   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    443 result(s) found for: Variants. Displaying page 1 of 23.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2007-004267-22 Sponsor Protocol Number: 2348/2007 Start Date*: 2007-11-15
    Sponsor Name:AZIENDA OSPEDALIERA PISANA
    Full Title: Pharmacogenetic evaluation of oxicodone in patients.
    Medical condition: Cancer chronic pain.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10058019 Cancer pain LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2013-002124-17 Sponsor Protocol Number: IMO-AFLI-2013-01 Start Date*: 2013-10-04
    Sponsor Name:Fundació de Recerca de L?Institut de Microcirurgia Ocular
    Full Title: Phase IV study to evaluate genetic variants of VEGF pathway as biomarkers of VEGF Trap-Eye treatment efficacy in subjects with neovascular age-related macular degeneration (wAMD).
    Medical condition: Wet age-related macular degeneration
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2022-002715-38 Sponsor Protocol Number: APHP220775 Start Date*: 2023-03-20
    Sponsor Name:Assistance Publique – Hôpitaux de Paris (AP-HP)
    Full Title: Immunogenicity and reactogenicity of the Beta-variant recombinant protein booster vaccine (VidPrevtyn Beta, Sanofi) compared to a bivalent mRNA vaccine (Comirnaty Original/Omicron BA.4-5, BioNTech...
    Medical condition: Adults who received at least 3 doses of mRNA Covid 19 vaccine (BioNTech-Pfizer and/or Moderna), the last dose received at least 6 months prior to the inclusion in the trial.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-000146-21 Sponsor Protocol Number: AT1001-020 Start Date*: 2019-08-29
    Sponsor Name:Amicus Therapeutics, UK Ltd
    Full Title: AN OPEN-LABEL STUDY OF THE SAFETY, PHARMACOKINETICS, PHARMACODYNAMICS, AND EFFICACY OF 12-MONTH TREATMENT WITH MIGALASTAT IN PEDIATRIC SUBJECTS (AGED 12 TO <18 YEARS) WITH FABRY DISEASE AND AMENABL...
    Medical condition: Fabry disease and with amenable GLA variants
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10016016 Fabry's disease PT
    Population Age: Adolescents, Under 18 Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) DE (Ongoing) ES (Completed) IT (Ongoing)
    Trial results: View results
    EudraCT Number: 2021-004526-29 Sponsor Protocol Number: uni-koeln-4602 Start Date*: 2021-10-19
    Sponsor Name:University of Cologne
    Full Title: A MULTINATIONAL, PHASE 2, RANDOMISED, ADAPTIVE PROTOCOL TO EVALUATE IMMUNOGENICITY AND REACTOGENICITY OF DIFFERENT COVID-19 VACCINES ADMINISTRATION IN OLDER ADULTS (≥75) ALREADY VACCINATED AGAINST ...
    Medical condition: Prevention of COVID-19 infection
    Disease: Version SOC Term Classification Code Term Level
    23.1 100000004865 10084464 COVID-19 immunization LLT
    23.1 100000004865 10084465 COVID-19 vaccination LLT
    24.0 100000004865 10085559 Revaccination with different COVID-19 vaccine LLT
    23.0 100000004865 10084462 SARS-CoV-2 vaccination LLT
    23.0 100000004865 10084463 SARS-CoV-2 immunisation LLT
    23.0 100000004865 10084466 SARS-CoV-2 immunization LLT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: DE (Completed) NO (Completed) IE (Completed) ES (Completed) LT (Completed)
    Trial results: View results
    EudraCT Number: 2011-006302-28 Sponsor Protocol Number: OXYGENE Start Date*: 2012-07-11
    Sponsor Name:UNIVERSITA' DEGLI STUDI DI PARMA
    Full Title: Dopamine modulation of oxytocin prosocial effects
    Medical condition: HEALTHY VOLUNTEERS. FOR PATIENTS WITH AUTISM OR SCHIZOPHRENIA
    Disease:
    Population Age: Adults Gender: Male
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2021-002873-24 Sponsor Protocol Number: RM-493-035 Start Date*: 2022-05-16
    Sponsor Name:Rhythm Pharmaceuticals Inc.
    Full Title: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study: 5 Independent Sub-studies of Setmelanotide in Patients with POMC, PCSK1, LEPR, SRC1, SH2B1, and PCSK1 N221D Gene Defects in the Melano...
    Medical condition: Specific Gene Defects in the Melanocortin-4 Receptor Pathway, responsible for improper functions of certain messenger materials in the body. E.g Melanocyte-Stimulating Hormone (MSH)
    Disease:
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) ES (Ongoing) DE (Trial now transitioned) GR (Trial now transitioned) NL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2009-011464-11 Sponsor Protocol Number: VX08-950-112 Start Date*: 2009-10-20
    Sponsor Name:Vertex Pharamceuticals, Inc.
    Full Title: EXTEND: A 3-Year, Virology, Follow-up Study in Subjects Previously Treated With Telaprevir in Select Clinical Studies
    Medical condition: Hepatitis C virus infection
    Disease: Version SOC Term Classification Code Term Level
    12.0 10019752 Hepatitis C virus (HCV) LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2021-006574-23 Sponsor Protocol Number: AR101-PREVEnt Start Date*: 2022-08-30
    Sponsor Name:Aytu BioPharma, Inc.
    Full Title: A multicenter, randomized, double-blind, placebo-controlled study of enzastaurin for the prevention of arterial events in patients with vascular Ehlers-Danlos Syndrome (vEDS) confirmed with COL3A1 ...
    Medical condition: vascular Ehlers-Danlos Syndrome (vEDS) confirmed with COL3A1 mutations
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10014316 Ehlers-Danlos syndrome PT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: SE (Ongoing) BE (Prematurely Ended) FR (Ongoing) NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2011-005672-42 Sponsor Protocol Number: HGS1006-C1112 Start Date*: 2013-06-11
    Sponsor Name:Human Genome Sciences, Inc. (a wholly owned subsidiary of GlaxoSmithKline PLC)
    Full Title: A Phase 3/4, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, 52-Week Study to Evaluate the Efficacy and Safety of Belimumab (HGS1006) in Adult Subjects of Black Race With Systemic Lupus...
    Medical condition: Systemic Lupus Erythematosus (SLE)
    Disease: Version SOC Term Classification Code Term Level
    19.1 100000004859 10025134 Lupus erythematosus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2018-002492-17 Sponsor Protocol Number: CLL-RT1 Start Date*: 2019-11-13
    Sponsor Name:Universität zu Köln
    Full Title: A prospective, open-label, multicentre Phase-II-Trial to evaluate the efficacy and safety of zanubrutinib (BGB-3111), a BTK Inhibitor, plus tislelizumab (BGB-A317), a PD-1 Inhibitor, for treatment ...
    Medical condition: Patients with previously untreated Richter Transformation or patients who responded to up to one prior line of RT therapy
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10008975 Chronic lymphocytic leukaemia variants LLT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned) AT (Trial now transitioned) DK (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2022-002329-84 Sponsor Protocol Number: APHP211039 Start Date*: 2023-01-06
    Sponsor Name:ASSISTANCE PUBLIQUE HOPITAUX DE PARIS (AP-HP)
    Full Title: Eculizumab in hypertensive emergency-associated hemolytic uremic syndrome: a randomized multicenter controlled trial.
    Medical condition: Adult patients with aHUS associated with HE and severe kidney involvement (needing dialysis or serum creatinine ≥ 354µM).
    Disease: Version SOC Term Classification Code Term Level
    20.1 10005329 - Blood and lymphatic system disorders 10079840 Atypical haemolytic uraemic syndrome PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2011-004570-28 Sponsor Protocol Number: HGS1006-C1121 Start Date*: 2012-09-13
    Sponsor Name:Human Genome Sciences, Inc. (a wholly owned subsidiary of GlaxoSmithKline PLC)
    Full Title: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Belimumab plus Standard of Care versus Placebo plus Standard of Care in Adult Subjects with Acti...
    Medical condition: Lupus Nephritis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10038359 - Renal and urinary disorders 10025140 Lupus nephritis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) DE (Completed) GB (Completed) BE (Completed) ES (Completed) CZ (Completed) NL (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2020-005756-37 Sponsor Protocol Number: CONTENTSS Start Date*: 2021-11-02
    Sponsor Name:Fundación Pública Andaluza para la Gestión de la
    Full Title: Double blind randomized clinical trial comparing noradrenaline plus placebo versus noradrenaline plus terlipressin in septic shock
    Medical condition: Patients with septic shock who remain without reaching the hemodynamic goal of TAM> 65 mmHg, despite volume replacement and administration of noradrenaline at doses equal to or greater than 0.2 μg ...
    Disease: Version SOC Term Classification Code Term Level
    23.1 10021881 - Infections and infestations 10040070 Septic shock PT
    20.0 10021881 - Infections and infestations 10040089 Septicemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2012-002096-34 Sponsor Protocol Number: AER-2012 Start Date*: 2012-10-29
    Sponsor Name:Crucell Holland B.V.
    Full Title: Research towards presence of Antibodies against European Bat Lyssavirus (EBLV) after immunization with Rabipur®
    Medical condition: healthy volunteers
    Disease: Version SOC Term Classification Code Term Level
    14.1 10042613 - Surgical and medical procedures 10069589 Rabies immunization LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2010-018559-84 Sponsor Protocol Number: AMB-WEI-1052-I Start Date*: 2010-07-20
    Sponsor Name:Medizinische Fakultät der technischen Universität Muenchen
    Full Title: AMBITIOUS Atopic Dermatitis Biomarker Identification Trial in Omalizumab Usage Single- arm trial to identify potential markers underlying variability in response to Omalizumab (Xolair®) treatment i...
    Medical condition: AMBITIOUS is a trial to identify potential markers underlying variability in response to Omalizumab (Xolair®) treatment in atopic dermatitis Atopische Dermatitis is a common inflammatory skin disea...
    Disease: Version SOC Term Classification Code Term Level
    14.0 10040785 - Skin and subcutaneous tissue disorders 10029264 Neurodermatitis aggravated LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2021-002186-17 Sponsor Protocol Number: volgt Start Date*: 2021-08-31
    Sponsor Name:RadboudUMC
    Full Title: Timing and sequence of vaccination against COVID-19 and Influenza
    Medical condition: Immunogenicity of the consecutive vaccination with both an mRNA COVID-19 vaccin and Influenza vaccin, in different sequences
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2022-002718-17 Sponsor Protocol Number: IMVT-1401-2401 Start Date*: 2023-06-19
    Sponsor Name:Immunovant Sciences, GmbH
    Full Title: A Phase 2b, Multi-center, Randomized, Quadruple-blind, Placebo-controlled Study of Batoclimab Treatment in Adult Participants with Active Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
    Medical condition: Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10077384 Chronic inflammatory demyelinating polyneuropathy LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned) NO (Trial now transitioned) BE (Trial now transitioned) FI (Trial now transitioned) SE (Trial now transitioned) DK (Trial now transitioned) SK (Trial now transitioned) PT (Trial now transitioned) BG (Trial now transitioned) ES (Ongoing) RO (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2021-000515-24 Sponsor Protocol Number: NL76470.078.21 Start Date*: 2021-02-15
    Sponsor Name:Erasmus University Medical Center
    Full Title: Vaccination Against Covid in Primary Immune Deficiencies
    Medical condition: Patients with primary immunodeficiency disease, also known as inborn errors pf immunity, are vaccinated against COVID-19 using COVID-19 Vaccine Moderna. The vaccine has been approved for use in the...
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004870 10036700 Primary immunodeficiency syndromes HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2021-001993-52 Sponsor Protocol Number: IMCOVAS Start Date*: 2021-05-20
    Sponsor Name:University of Antwerp
    Full Title: Assessment of the immunogenicity and safety of marketed vaccines for COVID-19 after regular schedule and adapted vaccine schedules and routes: BNT162b2 (Comirnaty®; Pfizer-BioNTech), mRNA-1273 Vacc...
    Medical condition: Coronavirus disease-19 (COVID-19)
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat May 10 00:26:21 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA